Takeda hikes outlook on cancer drug sales, Q3 profit jumps 60%

Tokyo

TAKEDA Pharmaceutical Co Ltd said that its annual profit will outstrip a prior estimate and reach a six-year high, boosted by stronger sales of the cancer drug Velcade, after earlier reporting better-than-expected quarterly earnings.

Velcade is used to treat multiple myeloma, a type of blood cancer. A US court last year upheld Takeda's patent, giving the drug maker rights to exclusively sell the drug until 2022.